Caplin Steriles gets USFDA approval for Labetalol Hydrochloride Injection USP

Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited (Caplin), a Subsidiary of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Labetalol Hydrochloride Injection USP, 100 mg/20 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL) Multiple-dose Vials, a generic therapeutic equivalent version of (RLD), TRANDATE Injection, of Sebela Ireland Limited.

Labetalol Hydrochloride Injection USP is indicated for control of blood pressure in severe hypertension. According to IQVIATM (IMS Health), Labetalol hydrochloride Injection had US sales data of approximately $6 million for the 12-month period ending June 2021.

Shares of Caplin Point Laboratories Ltd. was last trading in BSE at Rs. 821.1 as compared to the previous close of Rs. 838.5. The total number of shares traded during the day was 57905 in over 3600 trades.

The stock hit an intraday high of Rs. 855 and intraday low of 814. The net turnover during the day was Rs. 48572133.

Source : Equity Bulls

Keywords